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The aim of this study was to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of fosfomycin
against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains that have different fosfomycin MICs. Our
methods included the use of a hollow fiber infection model with three clinical ESBL-producing E. coli strains. Human fosfomy-
cin pharmacokinetic profiles were simulated over 4 days. Preliminary studies conducted to determine the dose ranges, including
the dose ranges that suppressed the development of drug-resistant mutants, were conducted with regimens from 12 g/day to 36
g/day. The combination of fosfomycin at 4 g every 8 h (q8h) and meropenem at 1 g/q8h was selected for further assessment. The
total bacterial population and the resistant subpopulations were determined. No efficacy was observed against the Ec42444
strain (fosfomycin MIC, 64 mg/liter) at doses of 12, 24, or 36 g/day. All dosages induced at least initial bacterial killing against
Ec46 (fosfomycin MIC, 1 mg/liter). High-level drug-resistant mutants appeared in this strain in response to 12, 15, and 18 g/day.
In the study arms that included 24 g/day, once or in a divided dose, a complete extinction of the bacterial inoculum was ob-
served. The combination of meropenem with fosfomycin was synergistic for bacterial killing and also suppressed all fosfomycin-
resistant clones of Ec2974 (fosfomycin MIC, 1 mg/liter). We conclude that fosfomycin susceptibility breakpoints (<64 mg/liter
according to CLSI [for E. coli urinary tract infections only]) should be revised for the treatment of serious systemic infections.
Fosfomycin can be used to treat infections caused by organisms that demonstrate lower MICs and lower bacterial densities, al-
though relatively high daily dosages (i.e., 24 g/day) are required to prevent the emergence of bacterial resistance. The ratio of the
area under the concentration-time curve for the free, unbound fraction of fosfomycin versus the MIC (fAUC/MIC) appears to be
the dynamically linked index of suppression of bacterial resistance. Fosfomycin with meropenem can act synergistically against
E. coli strains in preventing the emergence of fosfomycin resistance.
In recent decades, there has been an increase in infections causedby Enterobacteriaceae that produce extended-spectrum beta-lac-
tamases (ESBL). The most prevalent ESBL-producing species are
Escherichia coli and Klebsiella pneumoniae (1–3). ESBL-producing
Enterobacteriaceae are often resistant to other classes of antimicrobi-
als, such as fluoroquinolones, sulfamaethoxazole/trimethoprim, tet-
racyclines, and aminoglycosides. Carbapenems are considered the
drugs of choice for severe infections caused by ESBL producers
(4). However, the extensive use of carbapenems may be contrib-
uting to the spread of carbapenemases (5). The repurposing of old
antimicrobials with activity against drug-resistant Enterobacteria-
ceae is an important strategy to address the ever-present threat of
antimicrobial resistance. However, due to the scarcity of informa-
tion of the clinical value of these old drugs in well-designed stud-
ies, new clinical research trials are under way in order to reevaluate
the efficacy of these older drugs against the current gold standard
treatments (6).
Fosfomycin inhibits the formation of peptidoglycan via an in-
teraction with the protein UDP-N-acetylglucosamine enolpyruvyl
transferase (MurA). Inhibition of this enzyme results in decreased
formation of N-acetylmuramic acid (the peptidoglycan precur-
sor) from N-acetylglucosamine and phosphoenolpyruvate (7).
According to the current susceptibility breakpoints, fosfomycin is
active against the majority of ESBL-producing Enterobacteriaceae
(8, 9). An oral formulation of fosfomycin is widely available for the
treatment of acute uncomplicated urinary tract infection, and an
intravenous formulation is also available in some countries (10).
There is now renewed interest in using fosfomycin for the treat-
ment of serious systemic infections caused by multidrug-resistant
bacteria. However, there is a paucity of information related to the
pharmacokinetics (PK) and pharmacodynamics (PD) of fosfomy-
cin and considerable uncertainty regarding optimal regimens for
systemic infections.
An improved understanding of the pharmacokinetic-pharma-
codynamic relationships is a first critical step for the design of
fosfomycin regimens that are safe, effective, and prevent the emer-
gence of antimicrobial resistance (11). Here, we use a well-vali-
dated hollow fiber infection model (HFIM) to examine the PK
and PD of fosfomycin against three isolates of ESBL-producing E.
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coli that demonstrate a range of resistance mechanisms and MIC
values.
MATERIALS AND METHODS
Microorganisms. Three clinical, non-clonally related, ESBL-producing
E. coli isolates (Ec46 [CTX-M-15], Ec2974 [CTX-M-15], and Ec42444
[CTX-M-32]) were used. These strains were obtained from patients from
the University Hospital Virgen de Macarena. The strains were identified
to the species level by using a Bruker Biotyper matrix-assisted laser
desorption ionization–time of flight mass spectrometry (MS) system
(Bruker Daltonics, Billerica, MA) according to the manufacturer’s in-
structions. The ESBL enzymes (CTX-M-15 and CTX-M-32) were identi-
fied by sequencing and clonality based on pulsed-field gel electrophoresis
(data not shown).
Drugs. Fosfomycin disodium salt (Sigma-Aldrich, Dorset, United
Kingdom) and meropenem trihydrate (VWR, Leicestershire, United
Kingdom) were used for the susceptibility testing, time-kill assays, prep-
aration of drug-containing agar plates, and bioanalytical methods (ultra-
high-performance liquid chromatography/tandem mass spectrometry
[UHPLC/MS-MS] methods). Twenty-five milligrams per liter of glucose-
6-phosphate (G6P; Sigma-Aldrich) was added to the media used for
susceptibility testing, quantification of bacterial subpopulations in the
pharmacodynamic experiments, and the HFIM. Intravenous clinical
formulations of fosfomycin (Laboratorios ERN, Barcelona, Spain) and
meropenem (Ranbaxy Limited, London, United Kingdom) were used for
the HFIM experiments.
In vitro susceptibility testing. The in vitro susceptibility to fosfomy-
cin was measured using agar dilution according to CLSI methodology (9).
MICs were performed in triplicate. Cation-adjusted Mueller-Hinton agar
(Ca-MHA) plates (Becton-Dickinson, Sparks, MD) containing 25 mg/
liter G6P and fosfomycin in concentrations ranging from 0.25 to 1,024
mg/liter was prepared. A replicator with 1-mm pins was used to place
inocula of 1  104 CFU on the surface of the agar. Plates were incubated
for 16 to 20 h in ambient air at 35°C. The meropenem susceptibility
determination was performed using the standard broth microdilution
methodology according to CLSI standards (9). E. coli ATCC 25922 was
used as the quality control strain for these experiments.
Mutation frequency. An initial inoculum of 102 CFU/ml was incu-
bated overnight in Mueller-Hinton Broth and then plated on drug-free
Ca-MHA plates (to estimate the total bacterial concentration) and drug-
containing Ca-MHA plates (to estimate the subpopulation able to grow at
a predetermined antimicrobial concentration). All Ca-MHA plates were
supplemented with G6P. For meropenem, the bacterial suspension was
plated on Ca-MHA plates that were drug free or contained 3 or 4 mg/liter
of meropenem.
To investigate whether the mutants that grew on drug-containing
plates had an elevated MIC, 10 colonies were selected and the fosfomycin
and meropenem MICs were reestimated using agar dilution or the broth
microdilution method, as previously described.
Hollow fiber infection model. An HFIM was used to investigate the
pharmacodynamics of fosfomycin against three ESBL-producing E. coli
strains (12). Mueller-Hinton broth (MHB) was pumped from a central
compartment through a hollow fiber cartridge (FiberCell Systems, Fred-
erick, MD, USA) before being returned to the central compartment. A
peristaltic pump (model 205U; Watson-Marlow, United Kingdom) was
used. Fosfomycin and meropenem were administered to the central com-
partment by using a programmable syringe driver (Aladdin pump; World
Precision Instruments, United Kingdom). Fresh Ca-MHB was pumped
from a reservoir into the central compartment, and the same volume of
drug-containing medium was removed as waste. The rate at which this
occurred was controlled to simulate human pharmacokinetic profiles for
both drugs (i.e., an elimination half-life of 4 h for fosfomycin and 1 h for
meropenem [13, 14]).
The extracapillary space of each HFIM was inoculated with 40 ml of
bacterial suspension. The desired inoculum was confirmed with quanti-
tative cultures. The HFIM was incubated at 37°C in ambient air. Bacterial
densities were determined by removing 1 ml from the extracapillary space
via a sampling port. Serial dilutions in 100-l volumes were then plated
on both drug-free and drug-containing Ca-MH agar plates to enumerate
total and resistant subpopulations, respectively.
Drug concentrations. The fosfomycin and meropenem concentra-
tions were determined using an UHPLC/MS-MS triple-quadrupole 6420
mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) during
the first dosing interval and at steady state. One milliliter was drawn from
the central compartment at 1, 2, 4, 6, 8 and/or 12, and 24 h after drug
administration, depending on the regimen being studied. Samples were
immediately stored at 80°C until analysis.
A previously described method, with minor modification, was used to
measure fosfomycin concentrations (15). Instrument parameters were
optimized for fosfomycin (137.0 to 63 m/z) transitions. Fosfomycin was
extracted from Ca-MHB by diluting the broth with LC/MS-grade water
(Fisher Scientific, Loughborough, United Kingdom) with an internal
standard (IS). HPLC separation was achieved using a Luna 3-m CN
100-Å 50- by 2.0-mm column (Phenomenex, Torrance, CA, USA). The
mobile phase consisted of 0.1% formic acid in water and 0.1% formic acid
in acetonitrile at a flow rate of 0.35 ml/min. The column was maintained
at room temperature (22°C). The internal standard was 6,7-dimethyl-2,3-
di(2-pyridyl) quinoxaline (Sigma-Aldrich, Dorset, United Kingdom) at
0.125 ng/ml in water. The chromatographic run time for a sample was 2.5
min. The lower limit of quantitation of fosfomycin was 1 mg/liter. Intra-
day and interday coefficients of variation were 13.9% for concentrations
ranging from 1 to 75 mg/liter.
For meropenem, the instrument parameters were optimized (384.2 to
68.1 m/z transitions). Meropenem was extracted from Ca-MHB as de-
scribed above for fosfomycin. HPLC separation was achieved using a Zor-
bax Eclipse Plus 18 rapid-resolution 2.1- by 50-mm, 1.8-m column
(Agilent Technologies, Santa Clara, CA, USA). The mobile phases con-
sisted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile at
a flow rate of 0.4 ml/min. The column was maintained at room tempera-
ture (22°C). The internal standard was 6,7-dimethyl-2,3-di(2-pyridyl)
quinoxaline at 0.125 ng/ml in water. The chromatographic run time for one
sample was 2.5 min. The lower limit of quantitation of meropenem was 0.005
mg/liter. Intraday and interday coefficients of variation were 14.2% for
concentrations ranging from 0.005 to 8 mg/liter.
Fosfomycin pharmacokinetics and pharmacodynamics. The fosfo-
mycin concentration-time profiles were adjusted to mimic those observed
in humans (13). As plasma protein binding of fosfomycin has been re-
ported to be negligible (16), fosfomycin concentrations used in the HFIM
were assumed to constitute unbound fosfomycin. A one-compartment
PK model was fit to the in vitro fosfomycin concentration data. A popu-
lation methodology was employed using the program Pmetrics (17). The
structural model took the following form (equation 1):
dX1
dt
 R1  CLVc  X1 (1)
where X1 is the total amount of fosfomycin (in milligrams) in the central
compartment, R (in liters) is the infusion volume of fosfomycin into the
central compartment, CL (in liters per hour) is the clearance of fosfomy-
cin from the central compartment, and Vc (in liters) is the volume of the
central compartment.
Dose range-finding studies. The clinical strains Ec46 (MIC, 1 mg/
liter) and Ec42444 (MIC, 64 mg/liter) were used for the initial dose range-
finding studies in the HFIM. Human-like concentration-time profiles
corresponding to regimens of 4 g every 8 hours (q8h; 12 g/day), 8 g/q8h
(24 g/day), and 12 g/q8h (36 g/day) with an infusion time of 1 h were
generated. An initial bacterial density of 1  106 CFU/ml was used for
these experiments.
Determination of dose ranges that suppressed development of fos-
fomycin-resistant mutants. To determine the drug exposure concentra-
tions that suppressed the emergence of fosfomycin-resistant mutants, a
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dose range-finding study was conducted with strain Ec46 (MIC, 1 mg/
liter). Human-like concentration-time profiles of fosfomycin corre-
sponding to regimens of 4 g/q8h (12 g/day), 5 g/q8h (15 g/day), 6 g/q8h
(18 g/day), and 8 g/q8h (24 g/day), with each dosage infused over 1 h, or 24
g/q24h (24 g/day), delivered in a single bolus, were used. The pharmaco-
kinetic and pharmacodynamic data set was modeled via a population-
based methodology. The structural model took the following form (equa-
tions 2 and 3):
dCFUS
dt
 KgMAX-S  CFUS  1  CFUS  CFURPOPMAX 
 KkMAX-S  CFUS   CFOSHk-SCFOSHk-S  C50k-SHk-S  (2)
dCFUR
dt
 KgMAX-R  CFUR  1  CFUS  CFURPOPMAX 
 KkMAX-R  CFUR   CFOSHk-RCFOSHk-R  C50k-RHk-R  (3)
where KgMAX-S and KgMAX-R represent the maximal growth rate constants
for the susceptible and resistant populations (in CFU per millimeter per
hour), respectively; CFUS and CFUR are the numbers of the susceptible
and resistant organisms (in CFU per milliliter), respectively; POPMAX is
the maximal bacterial population (in CFU per milliliter), KkMAX-S and
KkMAX-R represent the maximal kill rate constants for the susceptible and
resistant populations (in CFU per milliliter per hour), respectively; CFOS is
the concentration of fosfomycin (in milligrams per liter); C50k-S and
C50k-R denote the concentrations for which the effect is half-maximal for
fosfomycin (in milligrams per liter) against the susceptible and resistant
populations, respectively; and Hk-S and Hk-R represent the slope functions
for killing of the sensitive and resistant populations, respectively.
Combination study of meropenem and fosfomycin. The impact of
fosfomycin-containing combination regimens on total bacterial killing
and prevention of emergence of drug resistance were assessed. The effect
of a clinically relevant regimen of fosfomycin at 4 g/q8h (1-h infusion) and
meropenem at 1 g/q8h (0.5-h infusion) was assessed. Strain Ec2974 (MIC
of 1 mg/liter for both fosfomycin and meropenem) was used for this
experiment. An initial bacterial concentration of 1010 CFU/ml was used
to promote the presence of resistant mutants (i.e., an inoculum in excess
of the inverse of the mutation frequency).
Drug interaction modeling. The interaction between fosfomycin and
meropenem was quantified by using a mathematical model, as previously
described (18). The interaction term was embedded in the bacterial kill
portion of a series of five inhomogeneous differential equations. Two
equations described the concentration-time profile of fosfomycin and
meropenem. The other three dealt with growth/death of a subpopulation
susceptible to both drugs, a population that was susceptible to fosfomycin
but resistant to meropenem, and a population that was susceptible to
meropenem but resistant to fosfomycin.
The system outputs were the following: (i) concentrations of drug 1;
(ii) concentrations of drug 2; (iii) total bacterial density (i.e., the sum of all
bacterial subpopulation densities); (iv) the bacterial density that was re-
sistant to fosfomycin but susceptible to meropenem; (v) the bacterial den-
sity that was resistant to meropenem but susceptible to fosfomycin. A
sixth differential equation (resistant to both drugs at baseline) was not
required. The full description of the model is provided in reference (18).
In order to identify drug interactions (synergy, additivity, and antag-
onism) in a statistically robust way, the mathematical model has as its
basis the definition of additivity (Loewe additivity) and identifies synergy
or antagonism as a statistically significant excursion from additivity. This
is accomplished by estimating the interaction parameter . If  is positive
and the lower end of the 95% confidence interval (CI) does not cross 0
(i.e., stays positive), then the interaction is a statistically significant syn-
ergy. If  is negative and the upper bound of the 95% confidence interval
does not cross 0 (i.e., stays negative), then the interaction is antagonistic.
Any time the 95% confidence bound around the point estimate of 
crosses 0, the interaction is additive. There is an  value for each bacterial
subpopulation. In this study, no meropenem-resistant clones were iso-
lated. Hence, there were two rather than three estimates for .
Population modeling was performed using the nonparametric adap-
tive grid (NPAG) program of Leary et al. (19). With respect to the model
published in reference 18, there was one difference in our model. Because
there were no resistant mutants identified until after 48 h in the fosfomy-
cin-alone arm, a lag time for the production of a mutant was incorporated
to allow for the substantial time from baseline for the emergence of a
resistant isolate.
RESULTS
In vitro susceptibility. The MIC for fosfomycin of strain Ec42444
was 64 mg/liter. For Ec46 and Ec2974, the MIC was 1 mg/liter.
Strain Ec2974 had an MIC of meropenem of 1 mg/liter.
Mutation frequency. Following 48 h of incubation, the fre-
quencies of Ec46 mutants able to grow on plates that contained
fosfomycin at 4 MIC, 16 MIC, 64 MIC, and 256 MIC
(MIC, 1 mg/liter) were 1.07  105, 2.66  106, 1.9  108,
and 7  108, respectively. The mutation frequencies for fosfo-
mycin for strain Ec2974 were 2.79  106, 1.17  107, 1.22 
109, and 1.22  109, respectively. The MICs of the recovered
strains were 64 mg/liter. For meropenem, the mutation fre-
quencies of Ec2974 at 3 MIC and 4 MIC (MIC, 1 mg/liter)
were 1.75 109 and 1.84  109, respectively.
Fosfomycin pharmacokinetics. A human-like profile was
generated by Pfausler et al. (13) and was based on the plasma
fosfomycin concentrations after intravenous administration of
fosfomycin at 8 g/q8h. With this dosage, the area under the con-
centration-time curve for the free, unbound fraction of the drug
from 0 to 24 h (fAUC0 –24) at steady state of 3,105 mg · h/liter was
observed in humans, which was similar to our result with the
human simulation dose, 8 g/q8h, where an fAUC0 –24 h of 3,136 mg
· h/liter was obtained. The other dosages were simulated, and the
pharmacodynamic parameters are shown in Table 1. For the
strains with a MIC of 1 mg/liter, the time above the MIC (TMIC)
covered the entire interval between doses. The observed and pre-
dicted concentrations are shown in Fig. 1.
Dose range-finding studies. All regimens of fosfomycin led to
rapid bactericidal activity against Ec46 (fosfomycin MIC, 1 mg/
liter). However, there was growth in the 12-g/day arm of a highly
resistant mutant that occurred after 24 h of treatment. Both 24
g/day and 36 g/day resulted in sterilization and complete suppres-
sion of drug-resistant mutants (Fig. 2A).
No efficacy was observed against the Ec42444 strain (fosfomy-
cin MIC, 64 mg/liter) with the three dosages evaluated (4 g/q8h
[12 g/day], 8 g/q8h [24 g/day], and 12 g/q8h [36 g/day]). With all
the regimens, there was a small initial reduction in bacterial bur-
den, but this was rapidly followed by growth of a resistant sub-
population (Fig. 2B).
Dose range-finding studies for suppression of development
of resistant mutants. To define the threshold of drug exposure
that suppressed the emergence of drug-resistant mutants, the ef-
fects of progressively higher dosages of fosfomycin were exam-
ined. All dosages induced at least initial bacterial killing. In the
arms receiving 12, 15, and 18 g of fosfomycin per day, there was
growth of a high-level drug-resistant mutant which appeared after
30 to 40 h of exposure to fosfomycin. For the two study arms that
received 24 g/day (i.e., 24 g once or in a divided dose), there was
complete extinction of the bacterial inoculum and no subsequent
emergence of drug resistance (Fig. 3). There was a clear delinea-
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tion of an exposure (24 g/day) that suppressed resistance and
eradicated the total population. Both 8 g every 8 h and 24 g once
daily achieved this goal, indicating that the dynamic index that
was best linked to resistance suppression was the fAUC/MIC ratio.
The results of the pharmacokinetic/pharmacodynamic model
are shown in Table 2. The fit of the model to the data (regression
analysis) included the following equations. For the observed ver-
sus predicted regression for all fosfomycin concentrations: Ob-
served  (1.071  Predicted)  6.57; R2  0.967. For the ob-
served versus predicted regression for all total colony counts:
TABLE 1 Pharmacodynamic parameters for fosfomycin obtained from the hollow fiber infection model
PD parameter
PD value for simulated human dosage (total dose/day) from:
Range-finding study Fractionation study
4 g/q8h (12 g) 8 g/q8h (24 g) 12 g/q8h (36 g) 6 g/q12h (12 g) 12 g/q24h (12 g)a 12 g/q24h (12 g)b
fAUC0–24 (mean) 1,744.94 3,136.03 4,287.82 2,121.83 2,366.83 2,404.61
fAUC0–24/MIC (MIC  1 mg/liter)
c 1,744.94 3,136.03 4,287.82 2,121.83 2,366.83 2,404.61
fAUC0–24/MIC (MIC  64 mg/liter)
d 27.26 49 67 33.15 36.98 37.57
a Data are for fosfomycin delivered in 1-h infusion.
b Data are for fosfomycin delivered via continuous infusion for 24 h.
c Data are for strain Ec46, for which the MIC is 1 mg/liter.
d Data are for strain Ec42444, for which the MIC is 64 mg/liter.
4g / 8 hours 6g / 8 hours
12g / 8 hours8g / 8 hours
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FIG 1 Pharmacokinetic profiles of the fosfomycin dosages used in the hollow fiber infection model. Solid lines, predicted concentrations; crosses, observed
concentrations.
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Observed  (1.067  Predicted)  0.892; R2  0.906. For the
observed versus predicted regression for fosfomycin-resistant col-
ony counts: Observed  (1.027  Predicted)  0.849; R2  0.903.
Combination of fosfomycin and meropenem. In order to
promote the emergence of drug resistant mutants, a high inocu-
lum was used (Fig. 4). Fosfomycin at 4 g/q8h (12 g/day) adminis-
tered as monotherapy reduced the bacterial concentrations by 3
log10 CFU/ml. However, mutants able to grow at 256 mg/liter
appeared after 48 h of treatment and, 24 h later, the resistant
mutants replaced the susceptible population.
On the other hand, meropenem at 1 g/q8h (3 g/day) alone
diminished the bacterial burden by approximately 6 log10 CFU/
ml. A reduction in the bactericidal activity was observed after 24 h.
However, no mutants (able to grow at 4 mg/liter) appeared after
96 h of treatment. Finally, the combination of fosfomycin at 4
g/q8h and meropenem at 1 g/q8h produced a 10-log10 CFU/ml
bacterial reduction, sterilizing the bacterial culture after 48 h. The
combination not only added an extra 4-log10 CFU/ml decline
compared to meropenem alone, but also completely suppressed
all clones resistant to fosfomycin at a dose of this drug (4 g/q8h)
that had previously allowed resistance emergence when employed
as monotherapy. The results of the interaction model showed a
synergistic effect for kill of the highly susceptible population ( 
4.78; 95% CI, 0.878 to 8.562) (Table 3). The fit of the model to the
data was as follows. For the observed versus predicted regression
for all meropenem concentrations: Observed  (1.142  Pre-
dicted)  0.874; R2  0.979. For the observed versus predicted
regression for all fosfomycin concentrations: Observed 
(0.985  Predicted) 	 1.089; R2  0.99. For the observed versus
predicted regression for all total colony counts: Observed 
(0.915  Predicted) 	 0.283; R2  0.903. For the observed versus
predicted regression for all total colony counts (fosfomycin resis-
tant): Observed  (1.142  Predicted)  0.874; R2  0.986.
DISCUSSION
Fosfomycin is a phosphonic acid derivative with broad-spectrum
antibacterial activity that often includes activity against organisms
that are resistant to other first-line antibacterial agents (20). Fos-
fomycin was discovered in 1969 and has generally been used to
treat uncomplicated urinary tract infections. Fosfomycin has a
low molecular mass (138 Da), is highly hydrophilic, and has neg-
ligible protein binding. It is well tolerated and penetrates urine
and most tissues, including the lung (21).
There is renewed interest in the use of fosfomycin for serious
systemic infections caused by multidrug-resistant Enterobacteria-
ceae (11, 22). The intravenous formulation of fosfomycin is li-
censed in a limited number of countries for use in serious systemic
infections (e.g., acute osteomyelitis, complicated urinary tract in-
fections, nosocomial lower respiratory tract infections, bacterial
meningitis, and bacteremia) that are caused by susceptible Gram-
positive and Gram-negative bacteria (23–25).
Fosfomycin is a phosphoenolpyruvate analogue that cova-
lently binds to amino acid residue Cys155 of MurA (UDP-GlcNAc
enolpyruvyl transferase). Binding prevents the first steps of pepti-
doglycan biosynthesis, which ultimately leads to bacterial cell lysis
and death (26). The glycerol-3-phosphate transporter (GlpT) and
a hexose phosphate transporter (UhpT) have been described as
the two main fosfomycin uptake transport systems in E. coli (26).
The addition of G6P increases the expression of these transport
proteins (UhpT), thus increasing the in vitro activity of fosfomy-
cin (27). The supplementation of growth medium with 25 mg/
liter G6P in the agar is part of the methodology for MIC determi-
nations when using both the CLSI and the EUCAST methods
(9, 28).
Our results with the E. coli isolate Ec2444, which had a fosfo-
mycin MIC of 64 mg/liter, demonstrated that fosfomycin is inef-
fective as a monotherapy against this less-susceptible strain. In
contrast, fosfomycin demonstrated a rapid and extensive bacteri-
cidal effect against the Ec46 strain, with an MIC of 1 mg/liter.
However, all fosfomycin regimens with a total daily dose of 24 g
per day resulted in the emergence of a resistant subpopulation
after 30 to 40 h of drug exposure. There were no detectable high-
level mutants (i.e., mutants able to grow in the presence of 256
mg/liter of fosfomycin) in the initial bacterial cultures, raising the
question as to whether these were present in small numbers that


















































FIG 2 Fosfomycin dose range-finding results with two ESBL-producing E. coli
strains. (A) Ec46 (MIC, 1 mg/liter); (B) Ec42444 (MIC, 64 mg/liter).
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absent. The latter case is more likely, simply because multiple sam-
ples were repeatedly negative. The appearance of highly resistant
mutants may reflect progressive adaption of a low-level mutant or
the development of sequential mutations that confer high-level
resistance to fosfomycin. The molecular basis of such events re-
quires further study: whether the appearance of mutants has any
clinical implications in immunocompetent patients must be stud-
ied, but monotherapy would not seem to be a good option for E.
coli infections in neutropenic and other immunosuppressed pa-
tients.
The pharmacodynamic index that best links drug exposure
with antimicrobial efficacy is important for an understanding of
the optimal use of fosfomycin (both in terms of bacterial killing
and/or preventing the emergence of resistant subpopulations).
Historically, fosfomycin has been considered an agent that exhib-
its time-dependent antibacterial activity (13, 29). In the current
study, dose fractionation studies were conducted with two ESBL-
producing strains with a fosfomycin MIC of 1 mg/liter. In both
cases, the administration of fosfomycin resulted in the same rate
and depth of bacterial killing, irrespective of the schedule of
FIG 3 Dose range-finding for suppression of development of fosfomycin-resistant mutants and fractionation studies with strain Ec46 (MIC, 1 mg/liter).
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administration (Fig. 3, hours 8 to 16). This is consistent with the
fAUC/MIC ratio being the pharmacodynamically linked index for
resistance suppression. It remains possible, however, that a max-
imal effect was induced, because all regimens had TMIC values of
100% (baseline MIC, 1 mg/liter).
As resistance emergence was consistently observed, the phar-
macodynamic index that is most closely linked to resistance sup-
pression is of substantial importance. In Fig. 3, doses of 8 g/q8h
(24 g/day) or 24 g q24h both completely suppressed resistance
amplification. This is strong evidence that the fAUC/MIC ratio is
linked to resistance suppression.
In serious infections, such as ventilator-acquired bacterial
pneumonia (VABP), the bacterial burden is often substantial and
can often exceed 9 log10 CFU/ml. We examined the utility of fos-
fomycin alone at the very dense inoculum of 1010 CFU/ml against
Ec2974. In this experiment, the activity of fosfomycin alone was
similar to that reported in the previous experiments, with a re-
growth of resistant mutants. Due to the inability to prevent the
appearance of mutants with monotherapy with fosfomycin for
treatment of high-inoculum infections, we designed a study to test
if the combination of fosfomycin (4 g/q8h) and meropenem (1 g/
q8h) could improve bacterial killing and prevent the emergence of
drug resistance. Meropenem alone resulted in increased killing




4 g/q8h (12 g) 5 g/q8h (15 g) 6 g/q8h (18 g) 8 g/q8h (24 g) 24 g/q24h (24 g)
V (liters) 36.01 37.57 37.82 39.20 39.36
SCL (liters/h) 5.54 5.47 6.16 6.11 6.07
KgMAX-S (CFU/ml/h) 5 5 4.43 3.46 2.7
KgMAX-R (CFU/ml/h) 1.17 1.161 1.15 2.04 0.7
KkMAX-S (CFU/ml/h) 7.21 7.14 8.3 3.81 4.31
KkMAX-R (CFU/ml/h) 0.97 0.97 0.94 3.38 1.38
C50k-S (mg/liter) 41.09 51.02 56.1 1.01 46.01
C50k-R (mg/liter) 5 5 5.02 5.54 41.94
Hk-S 12.43 13.36 1.33 13.4 5.07
Hk-R 17.9 17.83 19.04 17.61 0.5
POPMAX (CFU/ml) 1.72  10
10 7.94 109 1.43 1010 3 109 3 1010
INITCOND_2 (CFU/ml) 5.76 106 5.54 106 1 106 1 106 1.48 106
INITCOND_3 (CFU/ml) 1.69 102 1.69 102 1.69 102 1.73 102 4.71 102
a SCL is the fosfomycin clearance. INITCOND_2 and INITCOND_3 are the initial conditions for the total and resistant bacterial populations, respectively. Other parameter




















Total population Fosfomycin resistant population
Control (untreated)
Fosfomycin 4g/8h (12 g/day)
Meropenem 1g/8h (3 g/day)
Fosfomycin 4g/8h (12 g/day) +
Meropenem 1g/8h (3 g/day)
Control (untreated)
Fosfomycin 4g/8h (12 g/day)
Meropenem 1g/8h (3 g/day)
Fosfomycin 4g/8h (12 g/day) +
Meropenem 1g/8h (3 g/day)
Ec2974
FIG 4 Efficacy of fosfomycin (at 4 g/q8h) and meropenem (at 1 g/q8h) in
monotherapy and in combination against the Ec2974 strain in the HFIM.
TABLE 3 Parameter estimates from the mathematical model from the
drug combination study
Parametera Mean Median 95% CI
V1 (liters) 11.71 12.56 10.0–12.60
CL1 (liters/h) 6.21 5.98 4.84–7.80
V2 (liters) 29.12 28.22 25.91–33.09
CL2 (liters/h) 6.59 6.32 4.48–8.94
POPMAX
(CFU/ml)
1  1010 1  1010 1  1010–1.1  1010
Kg-S (CFU/ml/h) 1.59 1.50 1.27–2.00
Kk-S (CFU/ml/h) 2.43 2.21 2.08–3.00
E50_1S (mg/liter) 8.33 8.32 7.30–9.35
E50_2S (mg/liter) 13.51 14.84 10.00–15.75
_S 4.78 4.88 0.878–8.56
KgR-2 (CFU/ml/h) 0.70 0.20 0.101–1.79
KkR-2 (CFU/ml/h) 2.52 2.97 1.23–3.38
E50-2R2 (mg/liter) 34.33 28.22 22.13–52.52
_R2 0.41 0.48 4.84–5.49
INIT_3 (CFU/ml) 1  1010 1  1010 1  1010–1.1  1010
H1-S 12.19 11.95 10.71–13.89
H2-S 2.25 1.58 1.12–4.00
H2-R2 4.96 5.74 3.30–5.82
TLAG3 (h) 42.70 43.04 32.34–52.78
a For parameters that include a subscript numeral (1 or 2), 1 denotes a meropenem
parameter and 2 denotes a fosfomycin parameter. INIT_3 is the initial condition for the
total bacterial population. TLAG3 is the lag time for the fosfomycin-resistant mutants’
regrowth. E50 is the half-maximal effective concentration. _S and _R are the
interaction parameters between the antimicrobials for the susceptible and resistant
populations, respectively.
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relative to fosfomycin, but it did not result in extinction. We did
not observe any meropenem-resistant mutants, although it is pos-
sible that a low level of mutants was present but not detectable
(30).
The combination of fosfomycin and meropenem resulted in
a 
10-log10 CFU/ml kill and sterilization of the bacterial inocu-
lum after 48 h of treatment. The mathematical model demon-
strated a statistically significant synergistic interaction for killing
of the fully susceptible population (  4.78; 95% CI, 0.878 to
8.562) (Table 3). The interaction was also additive for the subpop-
ulation resistant to fosfomycin (  0.407; 95% CI, 4.84 to
5.49). This difference for the interaction being different for the
fully susceptible and less-susceptible populations has been previ-
ously observed, although in this case  was positive, suggesting a
favorable interaction of fosfomycin and meropenem (18). This
highly promising result requires further validation in an in vivo
setting, where immune effectors may contribute to the antimicro-
bial effect. The use of fosfomycin in vivo may result in the emer-
gence of different and biologically distinct mutations to those ob-
served in this study. Furthermore, the results may differ in the in
vivo setting because of the lack of G6P supplementation.
In conclusion, we have observed different aspects for the use of
fosfomycin against ESBL-producing E. coli strains. (i) The suscep-
tibility breakpoints established for fosfomycin, 32 mg/liter
(EUCAST) and 64 mg/liter (CLSI), for E. coli urinary tract in-
fections only, appear to be too high for the treatment of serious
systemic infections. (ii) Our results suggest that fosfomycin can be
used to treat infections with lower MICs and lower bacterial den-
sities, although relatively high daily dosages (i.e., 24 g/day) may be
required to prevent the emergence of bacterial resistance. (iii) The
fAUC/MIC appears to be the dynamically linked index for resis-
tance suppression. (iv) Until more data are available, fosfomycin
should not be used as monotherapy to treat systemic infections
with either high MICs or with high bacterial densities. (v) The
combination of fosfomycin and meropenem is synergistic and
prevents the emergence of drug resistance. Such a strategy may be
useful for the treatment of severe infections caused by ESBL-pro-
ducing E. coli strains. This study provides the experimental basis
for further clinical studies to identify optimal regimens of fosfo-
mycin for the treatment of serious systemic infections.
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